New, Simplified Treatment for ALL Hepatitis C Genotypes

Share

Follow Us

Print this page

Two Companies Enter into Hepatitis C Drug Development Deal

By Catherine Kolonko

Achillion Pharmaceuticals has joined forces with Janssen Pharmaceuticals to develop a short-duration oral regimen to treat chronic hepatitis C, the companies announced.

Both companies have entered into an exclusive worldwide license and collaboration arrangement to develop and commercialize one or more of Achillion’s lead hepatitis C treatments (currently named ACH-3102, ACH-3422) and sovaprevir, according to a release from Janssen, which is owned by Johnson & Johnson. The aim of the partnership will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of the hepatitis C virus, states a Janssen release.

Continue reading this entire article:
http://www.hcplive.com/medical-news/Two-Companies-Enter-into-Hepatitis-C-Drug-Development-Deal

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.